Blood Sugar; HighRCTNCT07141472
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
A study testing GB in people with Blood Sugar; High and Overweight and Obesity, run by Lawry Han at 1 site in United States.
Trial summary
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Blood Sugar; High, Overweight and Obesity, Fat Loss
- What is being tested?
- GB
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 69 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Jan 2025to 14 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Volunteers must be over the age of 18.
- Volunteers cannot be smokers.
- Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
- Exercising volunteers must maintain their regimen consistently throughout the course of the 26-week study.
- Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 26-week study.
- Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of a Glucagon-like Peptide-1 (GLP-1) Booster™ on Blood Glucose, HbA1c, Insulin, Glucagon, GLP-1, GIP, and Amylin Levels, Body Weight and Body Fat in Overweight Adult Men and Women
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
PURPOSE In prior study, GB was clinically shown to reduce blood sugar level, increase GLP-1 production, and help body fat loss. The purpose of this RCT study is to further assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula vs placebo, in the hope of confirming the efficacy and safety of GB.
SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, this study is a randomized controlled clinical trial for a total of 26 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints (week 0, 13 and 26).
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
- Being tested
- GB, Placebo
- Keywords
- GLP-1, blood glucose, HbA1c, insulin, glucagon, GIP, Amylin
- Medical subject headings
- Hyperglycemia, Overweight, Obesity, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GBDietary supplement
GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
PlaceboDietary supplement
Placebo is a product that resemble active GB but does not contain any of the active ingredients
| Study group | Role | What they receive |
|---|---|---|
| Active Group who take GB | Experimental | GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile. Receives: Dietary Supplement: GB |
| Placebo Group | Placebo comparator | Placebo is a product that resemble Active product but does not contain any of the active ingredients. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
fasting blood HbA1c level
lab
Measured: 26 weeks
fasting blood glucose level
lab
Measured: 26 weeks
fasting blood insulin level
lab
Measured: 26 weeks
fasting blood GLP-1 level
lab
Measured: 26 week
fasting blood glucagon level
lab
Measured: 26 weeks
fasting blood GIP level
lab
Measured: 26 weeks
fasting blood Amylin level
lab
Measured: 26 weeks
fasting body weight
measurement
Measured: 26 weeks
body fat mass
measurement
Measured: 26 week
waist hip ratio
measurement
Measured: 26 weeks
Secondary outcomes (5)
satiety score
questionnaire measuring satiety level from 1 - 10; the higher the score, the more satiety.
Measured: 26 weeks
resting metabolic rate
measurement
Measured: 26 weeks
Blood pressure
both systolic and diastolic pressures
Measured: 26 weeks
Heart rate
measurement
Measured: 26 weeks
Energy level
questionnaire measuring energy level from 1 - 10; the higher the score, the more energy.
Measured: 26 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2025
- Study start7 Jan 2025
- Primary completion15 Jul 2025
- Study completion14 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood Sugar; HighStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- RCT
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 69 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lawry Han
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor-investigator, Lawry Han, Alpine Biotech LLC
- Investigators
- Lawry Han, PhD, Principal investigator, Alpine Biotech
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07141472
- Sponsor's protocol ID
- AB20241210H
- Acronym
- RCT
- Status last verified
- Aug 2025
- First submitted
- 19 Aug 2025
- Last updated
- 3 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of a Glucagon-like Peptide-1 (GLP-1) Booster™ on Blood Glucose, HbA1c, Insulin, Glucagon, GLP-1, GIP, and Amylin Levels, Body Weight and Body Fat in Overweight Adult Men and Women
- ClinicalTrials.gov ID
- NCT07141472
- Acronym / sponsor ID
- RCT / AB20241210H
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
- Keywords
- GLP-1, blood glucose, HbA1c, insulin, glucagon, GIP, Amylin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 69 participants (actual)
- Lead sponsor
- Lawry HanIndustry (pharma, biotech, devices)
- Study start
- 7 Jan 2025 (actual)
- Primary completion
- 15 Jul 2025 (actual)
- Study completion
- 14 Aug 2025 (actual)
- First posted
- 26 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
PURPOSE In prior study, GB was clinically shown to reduce blood sugar level, increase GLP-1 production, and help body fat loss. The purpose of this RCT study is to further assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula vs placebo, in the hope of confirming the efficacy and safety of GB.
SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, this study is a randomized controlled clinical trial for a total of 26 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints (week 0, 13 and 26).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- RCT
| Arm | Type | Receives |
|---|---|---|
| Active Group who take GB | Experimental | Dietary Supplement: GBGLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile. |
| Placebo Group | Placebo comparator | Dietary Supplement: PlaceboPlacebo is a product that resemble Active product but does not contain any of the active ingredients. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Volunteers must be over the age of 18.
- Volunteers cannot be smokers.
- Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
- Exercising volunteers must maintain their regimen consistently throughout the course of the 26-week study.
- Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 26-week study.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GBGLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile. | Dietary supplement | Active Group who take GB |
| PlaceboPlacebo is a product that resemble active GB but does not contain any of the active ingredients | Dietary supplement | Placebo Group |
Primary outcome
fasting blood HbA1c level
Time frame: 26 weeks
lab
fasting blood glucose level
Time frame: 26 weeks
lab
fasting blood insulin level
Time frame: 26 weeks
lab
fasting blood GLP-1 level
Time frame: 26 week
lab
fasting blood glucagon level
Time frame: 26 weeks
lab
fasting blood GIP level
Time frame: 26 weeks
lab
fasting blood Amylin level
Time frame: 26 weeks
lab
fasting body weight
Time frame: 26 weeks
measurement
body fat mass
Time frame: 26 week
measurement
waist hip ratio
Time frame: 26 weeks
measurement
5 secondary outcomes
satiety score
Time frame: 26 weeks
resting metabolic rate
Time frame: 26 weeks
Blood pressure
Time frame: 26 weeks
Heart rate
Time frame: 26 weeks
Energy level
Time frame: 26 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Blood Sugar; High
Not yet recruitingObservational study
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
Obesity, Diabetes
Not yet recruiting
Effects of Mango on Insulin Sensitivity in Prediabetes
Pre Diabetes
Not yet recruitingEarly Phase 1
Efficacy of the pA1c®HI Postbiotic in Metabolic Regulation in Healthy Individuals With Hyperglycemia
Hyperglycemias, Prediabetes
Active, not recruiting
Insulin Balanced Infusion System
Hyperglycemia, Diabetes
Not yet recruitingObservational study
Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
End Stage Kidney Disease (ESKD), Hyperglycaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lawry Han, PhD principal investigator
Alpine Biotech
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing GB in people with Blood Sugar; High and Overweight and Obesity, run by Lawry Han at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
fasting blood HbA1c level (time frame: 26 weeks). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2025.